Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alliance Global Partners upgraded shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) from a neutral rating to a buy rating in a research report report published on Monday, The Fly reports. A number of other research firms have also issued reports on ALIM. Craig Hallum reduced their target price on shares of Alimera Sciences from […]
StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note released on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued reports about the stock. Craig Hallum dropped their target price on shares of Alimera Sciences from $18.00 to […]
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note published on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. A number of other equities analysts have also issued reports on the company. HC Wainwright lowered their price target on Alimera Sciences from $9.00 […]
StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. A number of other research firms have also weighed in on ALIM. Craig Hallum reduced their target price on shares of Alimera […]
EyePoint Pharmaceuticals is a $200m market cap biotech focused on eye disease. Read more to see a full investment analysis of EYPT stock.